Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy

The basics of epithelial-mesenchymal transition

Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · see citing works

Epithelial-Mesenchymal Transitions in Development and Disease

Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · see citing works

Targeting HIF-1 for cancer therapy

Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works

HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia

Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · see citing works

Cancer immunotherapy comes of age

Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · see citing works

The extracellular matrix: A dynamic niche in cancer progression

Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · see citing works

Modes of resistance to anti-angiogenic therapy

Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1× · see citing works

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. V. (2003) · Nature reviews. Molecular cell biology · doi:10.1038/nrm1261 · Cited by 2,667 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Hypoxia in cancer: significance and impact on clinical outcome

Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240 · see citing works

HIF-1: mediator of physiological and pathophysiological responses to hypoxia

Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822 · see citing works

VEGF as a Key Mediator of Angiogenesis in Cancer

Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,776 · see citing works

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712 · see citing works

VEGF-targeted therapy: mechanisms of anti-tumour activity

Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673 · see citing works

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635 · see citing works

TGF-β and epithelial-to-mesenchymal transitions

Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,580 · see citing works

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Jagt, D. L. V., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,528 · see citing works

Hypoxia-Induced Autophagy Is Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains

Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501 · see citing works

DNA Damage Produced by Ionizing Radiation in Mammalian Cells: Identities, Mechanisms of Formation, and Reparability

Ward, J. F. (1988) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60611-x · Cited by 1,499 · see citing works

General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.

Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468 · see citing works

Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1

Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463 · see citing works

HIF-1: upstream and downstream of cancer metabolism

Semenza, G. L. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.10.009 · Cited by 1,381 · see citing works

Lipid metabolism in cancer

Santos, C. R., & Schulze, A. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,344 · see citing works

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311 · see citing works

The discovery of receptor tyrosine kinases: targets for cancer therapy

Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · see citing works

Targeting lactate metabolism for cancer therapeutics

Doherty, J. R., & Cleveland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69741 · Cited by 1,173 · see citing works

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · see citing works

Hypoxia, DNA repair and genetic instability

Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140 · see citing works

Role of Tyrosine Kinase Inhibitors in Cancer Therapy

Arora, A., & Scholar, E. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,016 · see citing works

The ERBB network: at last, cancer therapy meets systems biology

Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 998 · see citing works

An overview of the c-MET signaling pathway

Organ, S. L., & Tsao, M. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 879 · see citing works

The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis: Figure 1

Greijer, A. E., & van der Wall, E. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015032 · Cited by 781 · see citing works

Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development

Baenke, F., Peck, B., Miess, H., & Schulze, A. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.011338 · Cited by 772 · see citing works

Hypoxia and cancer

Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765 · see citing works

Targeting the tumour vasculature: insights from physiological angiogenesis

Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2868 · Cited by 751 · see citing works

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF

Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730 · see citing works

Hypoxia and hypoxia-inducible factors: master regulators of metastasis

Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723 · see citing works

Hypoxia: A key regulator of angiogenesis in cancer

Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 720 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

Michelakis, E. D., Webster, L., & Mackey, J. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604554 · Cited by 657 · see citing works

Untitled work

(2003) · PubMed · Cited by 624 · see citing works

Hypoxia-induced autophagy: cell death or cell survival?

Mazure, N. M., & Pouysségur, J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.015 · Cited by 620 · see citing works

The MRP family of drug efflux pumps

Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 615 · see citing works

A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

Liu, Y., Cao, Y., Zhang, W., Bergmeier, S. C., Qian, Y., Akbar, H., Colvin, R. A., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 563 · see citing works

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies

Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559 · see citing works

Fatty Acid Synthase As a Potential Therapeutic Target in Cancer

Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. F. (2010) · Future Oncology · doi:10.2217/fon.10.11 · Cited by 545 · see citing works

HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo

Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523 · see citing works

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508 · see citing works

Regulation of EMT by TGFβ in cancer

Heldin, C., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 502 · see citing works

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480 · see citing works

Regulation of cancer cell metabolism by hypoxia-inducible factor 1

Semenza, G. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.009 · Cited by 469 · see citing works

Targeting the ERBB family in cancer: couples therapy

Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464 · see citing works

ERBB2 oncogene in human breast cancer and its clinical significance

Révillion, F., Bonneterre, J. M., & Peyrat, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10157-5 · Cited by 454 · see citing works

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0072 · Cited by 424 · see citing works

Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment

Moeller, B. J., Richardson, R. A., & Dewhirst, M. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9056-0 · Cited by 417 · see citing works

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400 · see citing works

Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol

Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, Ø., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395 · see citing works

Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1

Furuta, E., Pai, S. K., Zhan, R., Bandyopadhyay, S., Watabe, M., Mo, Y., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2489 · Cited by 392 · see citing works

Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression

Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., & Dang, C. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010189200 · Cited by 390 · see citing works

Emerging roles of PKM2 in cell metabolism and cancer progression

Luo, W., & Semenza, G. L. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.010 · Cited by 380 · see citing works

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380 · see citing works

Evaluation of HIF-1 inhibitors as anticancer agents

Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363 · see citing works

Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells

Bindra, R. S., Schaffer, P. J., Meng, A. X., Woo, J. M. P., Måseide, K., Roth, M. E., Lizardi, P. M., Hedley, D. W., Bristow, R. G., & Glazer, P. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8504-8518.2004 · Cited by 355 · see citing works

The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness

Wang, Z. P., Li, Y., Kong, D., et al. (2010) · Current Drug Targets · doi:10.2174/138945010791170860 · Cited by 342 · see citing works

Induction of Pyruvate Dehydrogenase Kinase-3 by Hypoxia-inducible Factor-1 Promotes Metabolic Switch and Drug Resistance

Lu, C.-W., Lin, S., Chen, K., Lai, Y.-Y., & Tsai, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803508200 · Cited by 331 · see citing works

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

Chan, N. H. L., Koritzinsky, M., Zhao, H. W., Bindra, R. S., Glazer, P. M., Powell, S. N., Belmaaza, A., Wouters, B. G., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328 · see citing works

Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction

Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M. J., Remacle, J., & Michiels, C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01359-9 · Cited by 324 · see citing works

The Met tyrosine kinase receptor in development and cancer

Gentile, A., Trusolino, L., & Comoglio, P. M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9107-6 · Cited by 319 · see citing works

Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1

Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301 · see citing works

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.

Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Meir, E. G. V., Simons, J. W., & Zhong, H. (2002) · PubMed · Cited by 299 · see citing works

Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways

Masson, N., & Ratcliffe, P. J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-3 · Cited by 296 · see citing works

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D. A., & Lee, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702387104 · Cited by 282 · see citing works

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269 · see citing works

EMT: A new vision of hypoxia promoting cancer progression

Jiang, J. D., Tang, Y., & Liang, X. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.8.15274 · Cited by 254 · see citing works

Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast

Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Campo, L., Chia, S., English, R. E., Pastorek, J., Sly, W. S., Ratcliffe, P. J., & Harris, A. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64048-5 · Cited by 249 · see citing works

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248 · see citing works

A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245 · see citing works

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

Sullivan, R., Paré, G. C., Frederiksen, L. J., Semenza, G. L., & Graham, C. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0198 · Cited by 241 · see citing works

Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells

Álvarez-Tejado, M., Naranjo‐Suarez, S., Jiménez, C., Carrera, A. C., Landázuri, M. O., & del Peso, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011688200 · Cited by 234 · see citing works

Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function

McNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013) · Immunologic Research · doi:10.1007/s12026-012-8349-8 · Cited by 234 · see citing works

Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer

Liu, L., Ning, X., Sun, L. J., Zhang, H., Shi, Y., Guo, C., Han, S., Liu, J., Sun, S., Han, Z., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00643.x · Cited by 226 · see citing works

Tumor hypoxia as a driving force in genetic instability

Luoto, K. R., Kumareswaran, R., & Bristow, R. G. (2013) · Genome Integrity · doi:10.1186/2041-9414-4-5 · Cited by 222 · see citing works

Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia

Cao, X., Fang, L., Gibbs, S. T., Huang, Y. S., Zunyan Dai, Y., Wen, P., Zheng, X., Sadée, W., & Sun, D. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0291-9 · Cited by 221 · see citing works

Lysyl Oxidase Mediates Hypoxic Control of Metastasis

Erler, J. T., & Giaccia, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3197 · Cited by 214 · see citing works

Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation

Muñoz-Nájar, U. M., Neurath, K. M., Vumbaca, F., & Claffey, K. P. (2006) · Oncogene · doi:10.1038/sj.onc.1209273 · Cited by 209 · see citing works

Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation

Holland, S. J., Powell, M. J., Franci, C., Chan, E. W., Friera, A. M., Atchison, R. E., McLaughlin, J. R., Swift, S. E., Pali, E. S., Yam, G. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0993 · Cited by 201 · see citing works

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D. J., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190 · see citing works

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3237 · Cited by 186 · see citing works

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W., Wu, D., Smaill, J. B., Patterson, A. V., & Ding, K. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10285 · Cited by 171 · see citing works

The extracellular matrix: A dynamic niche in cancer progression

Lu, P., Weaver, V. M., & Werb, Z. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem2093oia1 · Cited by 170 · see citing works

Overexpression of MMP-9 and HIF-1α in Breast Cancer Cells under Hypoxic Conditions

Choi, J. Y., Jang, Y. S., Min, S. Y., & Song, J. Y. (2011) · Journal of Breast Cancer · doi:10.4048/jbc.2011.14.2.88 · Cited by 164 · see citing works

Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1

Shin, D. H., Chun, Y., Lee, D. S., Huang, E. L., & Park, J. (2008) · Blood · doi:10.1182/blood-2007-11-120576 · Cited by 163 · see citing works

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159 · cited 1× · see citing works

Dysfunctional homologous recombination mediates genomic instability and progression in myeloma

Shammas, M. A., Reis, R. J. S., Koley, H., Batchu, R. B., Cheng, L., & Munshi, N. C. (2008) · Blood · doi:10.1182/blood-2007-05-089193 · Cited by 155 · see citing works

Met‐Related Receptor Tyrosine Kinase Ron in Tumor Growth and Metastasis

Wagh, P. K., Peace, B. E., & Waltz, S. E. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00001-8 · Cited by 154 · see citing works

Overexpression of Pyruvate Dehydrogenase Kinase 3 Increases Drug Resistance and Early Recurrence in Colon Cancer

Lu, C.-W., Lin, S.-C., Chien, C., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.050 · Cited by 141 · see citing works

A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts

Puri, N., Khramtsov, A., Ahmed, S., Nallasura, V., Hetzel, J. T., Jagadeeswaran, R., Karczmar, G. S., & Salgia, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4416 · Cited by 126 · see citing works

Tirapazamine: From Bench to Clinical Trials

Marcu, L. G., & Olver, I. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406775268192 · Cited by 125 · see citing works

HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs

Zhao, T., Zhu, Y., Morinibu, A., Kobayashi, M., Shinomiya, K., Itasaka, S., Yoshimura, M., Guo, G., Hiraoka, M., & Harada, H. (2014) · Scientific Reports · doi:10.1038/srep03793 · Cited by 121 · see citing works

Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells

Ding, Z., Li, Y., Xie, X., Xie, F., Pan, F., Li, J., He, J., & Liang, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0828-5 · Cited by 116 · see citing works

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0682 · Cited by 115 · see citing works

Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer

Mishra, A., Wang, J., Shiozawa, Y., McGee, S., Kim, J., Jung, Y., Joseph, J., Berry, J. E., Havens, A. M., Pienta, K. J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0569 · Cited by 112 · see citing works

The ABC Transporter Abcg2/Bcrp: Role in Hypoxia Mediated Survival

Krishnamurthy, P. C., & Schuetz, J. D. (2005) · BioMetals · doi:10.1007/s10534-005-3709-7 · Cited by 104 · see citing works

Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial

Matei, D. E., Schilder, J. M., Sutton, G. P., Perkins, S. M., Breen, T., Quon, C. Y., & Sidor, C. F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.042 · Cited by 101 · see citing works

Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2

Nakamura, H., Tanimoto, K., Hiyama, K., Yunokawa, M., Kawamoto, T., Kato, Y., YOSHIGA, K., Poellinger, L., Hiyama, E., & Nishiyama, M. (2008) · Oncogene · doi:10.1038/onc.2008.58 · Cited by 96 · see citing works

Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation

Notte, A., Ninane, N., Arnould, T., & Michiels, C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.167 · Cited by 96 · see citing works

Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.

Kondo, A., Safaei, R., Mishima, M., Niedner, H., Lin, X., & Howell, S. B. (2001) · PubMed · Cited by 95 · see citing works

The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance

Whelan, K. A., Schwab, L. P., Karakashev, S. V., Franchetti, L. D., Johannes, G. J., Seagroves, T. N., & Reginato, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426999 · Cited by 93 · see citing works

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

Fantin, V. R., St‐Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.011 · Cited by 91 · see citing works

EO9 (Apaziquone): from the clinic to the laboratory and back again

Phillips, R. M., Hendriks, H. R., Peters, G. J., & on behalf of the EORTC‐Pharmacology and Molecular Mechanism Group (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01996.x · Cited by 79 · see citing works

Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

Nilsson, M. B., Zage, P. E., Zeng, L., Xu, L., Cascone, T., Wu, H. K., Saigal, B., Zweidler‐McKay, P. A., & Heymach, J. V. (2010) · Oncogene · doi:10.1038/onc.2010.60 · Cited by 73 · see citing works

Effect of hypoxia-inducible factor-1α on transcription of survivin in non-small cell lung cancer

Chen, Y., Zhao, C., & Li, W. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-29 · Cited by 72 · see citing works

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks

Landgraf, R. (2007) · Breast Cancer Research · doi:10.1186/bcr1633 · Cited by 70 · see citing works

Hypoxia Suppression of Bim and Bmf Blocks Anoikis and Luminal Clearing during Mammary Morphogenesis

Whelan, K. A., Caldwell, S. A., Shahriari, K. S., Jackson, S. R., Franchetti, L. D., Johannes, G. J., & Reginato, M. J. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0353 · Cited by 70 · see citing works

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Vaishampayan, U. N., Burger, A. M., Sausville, E. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0503 · Cited by 63 · see citing works

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

McKeage, M. J., Jameson, M. B., Ramanathan, R. K., Rajendran, J. G., Gu, Y., Wilson, W. R., Melink, T. J., & Tchekmedyian, N. S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-496 · Cited by 63 · see citing works

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Falchook, G. S., Wheler, J. J., Naing, A., Jackson, E. F., Jankú, F., Hong, D. S., Ng, C. S., Tannir, N. M., Lawhorn, K., Huang, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2163 · Cited by 59 · see citing works

VHL: A very hip ligase

Tyers, M., & Rottapel, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12230 · Cited by 52 · see citing works

Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors

Faversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D., Rivadeneira, D. B., Altieri, D. C., & Bòsari, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3666 · Cited by 51 · see citing works

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma: An Illinois cancer center study

Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs · doi:10.1007/bf00872868 · Cited by 49 · see citing works

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2

Karakashev, S. V., & Reginato, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.2806 · Cited by 46 · see citing works

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts

Williams, K. J., Albertella, M. R., Fitzpatrick, B. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0396 · Cited by 46 · see citing works

Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia

Karar, J., Cerniglia, G. J., Lindsten, T., Koumenis, C., & Maity, A. M. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21144 · Cited by 43 · see citing works

Lasting longer without oxygen: The influence of hypoxia on Notch signaling

Pear, W. S., & Simon, M. C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.016 · Cited by 41 · see citing works

Hypoxia-Induced Collagen Synthesis of Human Lung Fibroblasts by Activating the Angiotensin System

Liu, S., Wang, H.-Y., Tang, J., & Zhou, X. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224029 · Cited by 36 · see citing works

Recepteur d'Origine Nantais Tyrosine Kinase Is a Direct Target of Hypoxia-inducible Factor-1α-mediated Invasion of Breast Carcinoma Cells

Thangasamy, A., Rogge, J., & Ammanamanchi, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809320200 · Cited by 35 · see citing works

The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness

Wang, Z. P., Li, Y., Kong, D., et al. (2010) · Current Drug Targets · doi:10.2174/1389210200418444501 · Cited by 34 · see citing works

Hypoxia Promotes Nuclear Translocation and Transcriptional Function in the Oncogenic Tyrosine Kinase RON

Chang, H., Liu, H., Lai, M.-D., Tsai, Y., Tzai, T., Cheng, H.-L., & Chow, N.-H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3730 · Cited by 33 · see citing works

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer

Glück, A. A., Aebersold, D. M., Zimmer, Y., & Medová, M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.02.018 · Cited by 26 · see citing works

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

Funakoshi, Y., Mukohara, T., Tomioka, H., Ekyalongo, R. C., Kataoka, Y., Inui, Y., Kawamori, Y., Toyoda, M., Kiyota, N., Fujiwara, Y., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9959-2 · Cited by 24 · see citing works

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells

Glazer, P. M., Bindra, R. S., Schaffer, P. J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(04)01188-5 · Cited by 19 · see citing works

Aberrant type I and type III collagen gene expression in human breast cancerin vivo

Kauppila, S., Stenbäck, F., Risteli, J., Jukkola, A., & Risteli, L. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(1998110)186:3

Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy

Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332 · see citing works

Mechanisms of Taxane Resistance

Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198 · see citing works

3D Bioprinting of Breast Cancer Models for Drug Resistance Study

Wang, Y., Shi, W., Kuss, M., Mirza, S., Qi, D., Krasnoslobodtsev, A., Zeng, J., Band, H., Band, V., & Duan, B. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01277 · Cited by 157 · see citing works

Hypoxia: a Double-Edged Sword in Cancer Therapy

Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1245317 · Cited by 147 · see citing works

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance

Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133 · see citing works

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy

Shurin, M. R., & Umansky, V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159473 · Cited by 113 · see citing works

Hypoxia Signaling in Cancer: From Basics to Clinical Practice

Sebestyén, A., Kopper, L., Dankó, T., & Tímár, J. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.1609802 · Cited by 110 · see citing works

Specific inhibition of HIF activity: can peptides lead the way?

Mylonis, I., Chachami, G., & Simos, G. (2021) · Cancers · doi:10.3390/cancers13030410 · Cited by 21 · see citing works

Hypoxia-inducible factor 1 (HIF1A; HIF1); endothelial PAS domain protein 1 (EPAS1; HIF2A); hypoxia-inducible factor prolyl hydroxylase (EGLN2; HIF-PHD; EGLN)

(2009) · Science-Business eXchange · doi:10.1038/scibx.2009.71

Analysis of the hypoxia inducible factor 1 alpha subunit (HIF1A)-dependent transcriptome during S. aureus infection in human HepG2 hepatocellular carcinoma cells

Beerlage, C. (2019) · Signaling Pathways Project Datasets · doi:10.1621/yusoalemlx

Analysis of hypoxia inducible factor 1 alpha subunit (HIF1A)- and endothelial PAS domain protein 1 (EPAS1)-dependent transcriptomes in human HepG2 hepatocellular carcinoma cells

Geis, T. (2019) · Signaling Pathways Project Datasets · doi:10.1621/fsyn7dx6ka

von Hippel–Lindau tumor suppressor (VHL); hypoxia-inducible factor 1 (HIF1A; HIF1)

(2009) · Science-Business eXchange · doi:10.1038/scibx.2009.94

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN); hypoxia-inducible factor 1α (HIF1A; HIF1α)

(2013) · Science-Business eXchange · doi:10.1038/scibx.2013.94